Cargando…
The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease
OBJECTIVE: We calculated the short- and long-term care resource use and costs in adults with high-risk conditions for cardiovascular disease (HRCVD) as defined by the Canadian Cardiovascular Society dyslipidemia guidelines. METHODS: We linked Alberta health databases to identify patients aged ≥ 18 y...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333236/ https://www.ncbi.nlm.nih.gov/pubmed/33484443 http://dx.doi.org/10.1007/s41669-021-00257-8 |
_version_ | 1783732984077090816 |
---|---|
author | Tran, Dat T. Palfrey, Dan Welsh, Robert |
author_facet | Tran, Dat T. Palfrey, Dan Welsh, Robert |
author_sort | Tran, Dat T. |
collection | PubMed |
description | OBJECTIVE: We calculated the short- and long-term care resource use and costs in adults with high-risk conditions for cardiovascular disease (HRCVD) as defined by the Canadian Cardiovascular Society dyslipidemia guidelines. METHODS: We linked Alberta health databases to identify patients aged ≥ 18 years with HRCVD between fiscal year (FY) 2012 and FY2016. The first HRCVD event was the index event. Patients were categorized into (1) primary prevention patients and (2) secondary prevention patients at the index event and were followed until death, they moved out of the province, or they were censored at March 2018. We calculated the resource use and costs for each of the 5 years after the index event. RESULTS: The study included 459,739 HRCVD patients (13,947 [3%] were secondary prevention patients). The secondary prevention patients were older (median age 61 years vs. 55 years; p < 0.001), and there were fewer females in this group (30.4% vs. 51.3%; p < 0.001). The total healthcare costs in the first year decreased over time (FY2012: 1.16 billion Canadian dollars (CA$); FY2016: CA$1.05 billion; p < 0.001). An HRCVD patient incurred CA$12,068, CA$5626, and CA$4655 during the first, second, and fifth year, respectively (p for trend < 0.001). During the first year, healthcare costs per secondary prevention patient (CA$36,641) were triple that for a primary prevention patient (CA$11,299; p < 0.001), primarily due to higher hospitalization costs in secondary prevention patients (CA$26,896 vs. CA$6051; p < 0.001). CONCLUSIONS: The healthcare costs for HRCVD patients were substantial but decreased over time. The costs were highest in the year following the index event and decreased thereafter. Secondary prevention patients incurred higher costs than the primary prevention patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-021-00257-8. |
format | Online Article Text |
id | pubmed-8333236 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-83332362021-08-20 The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease Tran, Dat T. Palfrey, Dan Welsh, Robert Pharmacoecon Open Original Research Article OBJECTIVE: We calculated the short- and long-term care resource use and costs in adults with high-risk conditions for cardiovascular disease (HRCVD) as defined by the Canadian Cardiovascular Society dyslipidemia guidelines. METHODS: We linked Alberta health databases to identify patients aged ≥ 18 years with HRCVD between fiscal year (FY) 2012 and FY2016. The first HRCVD event was the index event. Patients were categorized into (1) primary prevention patients and (2) secondary prevention patients at the index event and were followed until death, they moved out of the province, or they were censored at March 2018. We calculated the resource use and costs for each of the 5 years after the index event. RESULTS: The study included 459,739 HRCVD patients (13,947 [3%] were secondary prevention patients). The secondary prevention patients were older (median age 61 years vs. 55 years; p < 0.001), and there were fewer females in this group (30.4% vs. 51.3%; p < 0.001). The total healthcare costs in the first year decreased over time (FY2012: 1.16 billion Canadian dollars (CA$); FY2016: CA$1.05 billion; p < 0.001). An HRCVD patient incurred CA$12,068, CA$5626, and CA$4655 during the first, second, and fifth year, respectively (p for trend < 0.001). During the first year, healthcare costs per secondary prevention patient (CA$36,641) were triple that for a primary prevention patient (CA$11,299; p < 0.001), primarily due to higher hospitalization costs in secondary prevention patients (CA$26,896 vs. CA$6051; p < 0.001). CONCLUSIONS: The healthcare costs for HRCVD patients were substantial but decreased over time. The costs were highest in the year following the index event and decreased thereafter. Secondary prevention patients incurred higher costs than the primary prevention patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-021-00257-8. Springer International Publishing 2021-01-23 /pmc/articles/PMC8333236/ /pubmed/33484443 http://dx.doi.org/10.1007/s41669-021-00257-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Tran, Dat T. Palfrey, Dan Welsh, Robert The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease |
title | The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease |
title_full | The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease |
title_fullStr | The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease |
title_full_unstemmed | The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease |
title_short | The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease |
title_sort | healthcare cost burden in adults with high risk for cardiovascular disease |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333236/ https://www.ncbi.nlm.nih.gov/pubmed/33484443 http://dx.doi.org/10.1007/s41669-021-00257-8 |
work_keys_str_mv | AT trandatt thehealthcarecostburdeninadultswithhighriskforcardiovasculardisease AT palfreydan thehealthcarecostburdeninadultswithhighriskforcardiovasculardisease AT welshrobert thehealthcarecostburdeninadultswithhighriskforcardiovasculardisease AT trandatt healthcarecostburdeninadultswithhighriskforcardiovasculardisease AT palfreydan healthcarecostburdeninadultswithhighriskforcardiovasculardisease AT welshrobert healthcarecostburdeninadultswithhighriskforcardiovasculardisease |